UK sugar and sweeteners firm Tate & Lyle has said that since its update on 28 January its overall trading has remained in line with its expectations, with Staley performing slightly better and Amylum slightly worse.

The company said its outlook for 2005 remains unchanged.

“The annual sweetener pricing round in the US is now essentially complete with outcomes within our forecast range,” the company said.

Tate & Lyle added that its sugar operations in Europe, Canada and Mexico continue to perform in line with expectations and generate strong cash flow for the group. 

“Whilst, as expected, a working capital cash outflow is forecast for the financial year (in part due to higher raw material prices), net debt is expected to benefit from exchange translation,” the company said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last month Tate & Lyle announced the acquisition of the sucralose manufacturing plant and ingredients business of McNeil Nutritionals. The company said in its trading update that the acquisition remains on track for completion in early April 2004.